Author: CRST

Training Residents to Implant Premium IOLs

Residency is the critical link in transforming a medical
student into a practicing ophthalmologist. During
this 3-year training period, residents must learn how
to diagnose and care for patients and perform procedures
across the range of ophth…

What Is New in the US Pipeline?

A number of promising technologies are either
entering into or emerging from the US development
and regulatory pipeline. These technologies
range from therapeutics to diagnostics,
all playing an important role in advanced ocular
surgery. This…

A Bent-Tip Phaco Needle Is More Efficient

Surgeons’ adoption of transversal phacoemulsification
has been slower than some might have
expected. Although it is a significant technological
advance forward, some have not been
comfortable with the technology because, when it was
first d…

Post-LASIK Ectasia

h3LEELA RAJU, MD/h3

The slight claw-like pattern on the earlier topographies
may have suggested that the patient’s corneas were not
completely normal. The fact that he could not be corrected
to 20/20 on a subsequent visit is also conce…

Why LASIK Will Become a Rite of Passage

For young people today, the idea of treating refractive
errors with LASIK is a familiar and wellestablished
one. Having grown up hearing about
LASIK and possibly witnessing their parents’ experience
with the procedure, this generation has ne…

5 Questions With David W. Shoemaker, MD

h3What inspired you to found the
Center For Sight?/h3

The inspiration behind the founding of
the Center For Sight is best captured by the
practice’s mission statement, which is to
bring clear vision to life through caring and
trustin…

Two Acquisitions Announced

Alcon Laboratories, Inc., acquired the ophthalmic division
of SensoMotoric Instruments, according to a company
news release. The acquisition provides Alcon with
ocular surgical guidance technology for use in cataract
surgery, such as real-time eye trac…

InSite Vision Completes Phase 3 Clinical Study of BromSite

The final patient has completed dosing and evaluation
in InSite Vision’s phase 3 clinical trial of BromSite (ISV-
303) for the reduction of pain and inflammation after
cataract surgery. BromSite combines a low dose (0.075%)
of the agent bromfenac with InSite Vision’s DuraSite
drug-delivery technology. Top-line data…

Allergan to Buy MAP Pharmaceuticals for $958 Million

Allergan, Inc., has agreed to pay nearly $1 billion to
acquire MAP Pharmaceuticals, a biopharmaceutical company
focused on developing and commercializing new
therapies in neurology, the two companies announced in
a news release. The purchase price of $25 a share in cash
is a 60% premium over MAP’s closing price of $1…

Obama Honors LASIK Inventor

Gholam Peyman, an Arizona surgeon and inventor
of LASIK surgery, was honored at the White House
this month by President Barack Obama along with
10 other inventors receiving the National Medal of
Technology and Innovation.

Dr. Peyman practices at Arizo…